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Background: The goal of this study was to assess the association between endometrial thickness on the chorionic
gonadotropin (hCG) day and in vitro fertilization and embryo transfer (IVF-ET) outcome in normal responders after
GnRH antagonist administration.
Methods: A retrospective cohort study was performed in normal responders with GnRH antagonist administration
from January 2011–December 2013. Patients were divided into four groups according to endometrial thickness, as
follows: <7 mm (group 1), > = 7- < 8 mm (group 2), > = 8- < 14 mm (group 3), and > =14 mm (group 4).
Results: A total of 2106 embryo transfer cycles were analyzed. The pregnancy rate (PR) was 44.87%.The clinical
pregnancy rate, ongoing pregnancy rate and the implantation rate (17.28%, 13.79%, 10.17%, respectively) were
significantly lower in group 1 compared to the other three groups (p < 0.05). The miscarriage rate was higher in
patients with endometrial thickness less than 7 mm. The clinical pregnancy rate, ongoing pregnancy rate and
implantation rate were highest in patients with endometrial thickness higher than 14 mm, but showed no
difference in patients with those of endometrial thickness between 8-14 mm.
Conclusions: There is a correlation between endometrial thickness measured on hCG day and clinical outcome in
normal responders with GnRH antagonist administration. The pregnancy rate was lower in patients with
endometrial thickness less than 7 mm compared with patients with endometrial thickness more than 7 mm.
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In-vitro fertilization (IVF) and intracytoplasmic sperm
injection (ICSI) are widely accepted as effective treatment
for most causes of infertility. Gonadotropin-releasing hor-
mone (GnRH) antagonist is now widely used in controlled
ovarian stimulation cycles, which requires less follicle
stimulation, and has lower risk for ovarian hyperstimula-
tion syndrome (OHSS) [1,2]. A randomized controlled
trial (RCT) showed that normal responders treated with
the GnRH antagonist protocol exhibited the same high* Correspondence: xixiaowei1966@126.com
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unless otherwise stated.success rates as patients treated with the long GnRH
agonist protocol. The GnRH antagonist protocol is as
effective and safe as the long GnRH agonist protocol [3].
Age, quality of the embryo and endometrial receptivity
are the most important factors for the success of IVF.
Endometrial thickness (EMT) has been accepted as an
indicator for endometrial receptivity, and assessment of
the endometrium in the midsagittal plane via transvagi-
nal ultrasound is the standard procedure. Several studies
have shown a significant correlation between pregnancy
rate and endometrial thickness [4-7]. These studies re-
ported a threshold of <7 mm with a significant reduction
in the implantation rate and pregnancy rate. Recently
the first systematic review and meta-analysis investi-
gated both the independent predictive capacity and the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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outcomesafter IVF. This study found that the probability
of clinical pregnancy for an endometrial thickness ≤7 mm
was significantly lower compared with cases with endo-
metrial thickness >7 mm (23.3% versus 48.1%) and OR
was 0.42 (95% CI 0.27–0.67) [5]. There are few studies
examining the association between endometrial thickness
and clinical outcome in the GnRH antagonist protocol.
The aim of this study was to assess the association
between endometrial thickness on the HCG day and IVF
outcome in normal responders after GnRH antagonist
administration.
Methods
This study was reviewed and approved by the Institu-
tional Review Board and Ethics Committee of Shanghai
First People’s Hospital, China. This study is a retrospect-
ive cohort study and analyzed 2106 normal responders
in International Peace MCH Hospital Shanghai Jiaotong
University. All fresh embryo transferred patients after
GnRH antagonist administration between Jan. 2011 and
Dec. 2013 was included except poor responders accord-
ing to the Bologna criteria [8] and patients with polycys-
tic ovary syndrome (PCOS). Patients with abnormal
uterine cavity per HSG or hysteroscopy were excluded
from this study.
rFSH/HMG (rFSH-Gonal F-Merck Serono, Puregon-
MSD, HMG Lizhu China) was initiated at a dosage of 150
U-225 U per day on day 2 of the cycle. The ovarian
response was monitored by ultrasound and serum LH, E2
and P on day 6 (stimulation day 5). The need for add-
itional doses of rFSH/HMG was determined based onpregnancy rate %
 
Figure 1 Clinical pregnancy rates according to endometrial thicknessfollicular maturation, as assessed by ultrasound and E2
measurement. The GnRH antagonist (Cetrotide 0.25 mg-
Merck Serono) 0.25 mg/day was added when at least 1
follicle reached 14 mm in diameter until hCG administra-
tion. When at least three follicles had reached a diameter
of 18 mm, a dose of hCG (hCG, Lizhu China) 6000 U was
given and oocyte retrieval was performed 36 hours later
using vaginal ultrasound guided follicle aspiration. The
endometrial thickness was measured in the midsagittal
plane via transvaginal ultrasound on the day of hCG
administration. A maximum of 3 embryos were trans-
ferred after 2 or 3 days in culture.
Luteal support was administered by intramuscular
progesterone (dose 40 mg/day) beginning on the day of
oocyte retrieval.
Clinical pregnancy was defined as the presence of at
least a gestational sac on ultrasound 28 days after
embryo transfer. Ongoing pregnancy was defined as the
presence of at least one fetus with heart activity more
than 12 gestational weeks. Implantation rate was calcu-
lated as the number of sacs with fetal heart beat over
total embryos transferred.
All patients were divided into one of the following
four groups according to their endometrial thickness:
group 1 (n = 29): <7 mm; group 2 (n = 162): ≥7 mm
to <8 mm; group 3 (n = 1852): ≥8 mm to <14 mm; group 4
(n = 64): ≥14 mm.Statistical methods
Statistical analysis was performed using the statistical
package for Social Sciences (version 14, SPSS Inc, Chicago.
Table 1 Demographic and pretreatment characteristics
Group 1 Group 2 Group 3 Group 4
N = 29 N = 162 N = 1852 N = 63
Mean age 33.12 ± 3.46 32.34 ± 4.02 31.89 ± 3.67 31.98 ± 4.16
No. of Previous IVF attempts
None 15(51.72%)* 124(76.54%) 1390(75.05%) 51(80.95%)
One 10(34.48%) 30(18.51%) 374(20.19%) 11(17.46%)
Two or more 4(13.79%) 8(4.94%) 87(4.70%) 1(1.75%)
Baseline FSH(U) 7.84 ± 2.44 8.13 ± 2.12 8.87 ± 5.28 8.89
Baseline E2 (pmol/L) 167.71 ± 90.66 184.48 ± 160.48 169.85 ± 253.51 132.88 ± 57.19
*P < 0.05.
Wu et al. Reproductive Biology and Endocrinology 2014, 12:96 Page 3 of 5
http://www.rbej.com/content/12/1/96IL). The X2 test, t-test and ANOVA were used. P <0.05
was considered as statistically significant.
Results
A total of 2106 women aged 21–39 with fresh embryo
transfer were included in the analysis. The endometrial
thickness on the hCG day ranged from 5 mm to 18.7 mm.
The overall pregnancy rate was 44.87%. The clinical preg-
nancy rate was significantly lower in cases with endomet-
rial thickness below 7 mm. In addition, no pregnancy was
observed in the patients with endometrial thickness less
than 6 mm (Figure 1). According to the pregnancy rate in
Figure 1 (Group1: pregnancy rate <30%, Group2: preg-
nancy rate 30-40%, Group 3: pregnancy rate 40-50% and
Group 4: pregnancy rate >50%), the patients were divided
into 4 groups as previously described.
The demographic characteristics of the groups are
shown in Table 1. Age, baseline FSH, and baseline E2 were
similar among the four groups. More patients in Group 1
had a previous IVF attempt. Identical results were ob-
tained among these groups with regard to the duration of
ovarian stimulation, duration of GnRH antagonist admin-
istration, and serum E2 concentration on hCG day
(Table 2). There were no significant differences among
these groups. Moreover, the retrieved oocyte number,
transferred embryo number, fertilization rate and cleavage
rate were similar among these groups (Table 3).
The clinical pregnancy rate, ongoing pregnancy rate and
implantation rate increased with an increase in endomet-
rial thickness. The clinical pregnancy rate, ongoing rate
and implantation rate (17.28%, 13.79%, 10.17%, respect-
ively) were lowest in group 1 and were significantly lowerTable 2 Outcome of ovarian stimulation
Group 1 Group
N = 29 N = 16
Total dose of Gn 2137.3 2109.1
Duration of Gn 8.55 ± 1.45 8.52 ±
Duration of antagonist 3.68 ± 0.81 3.59 ±
Serum E2 on hCG day 9238 ± 1902.29 10457than the other three groups (p < 0.05). The miscarriage
rate was higher in patients with endometrial thickness less
than 7 mm. Among patients with endometrial thickness
between 7 mm to 8 mm, the clinical pregnancy rate and
implantation rate was lower than that of patients with
endometrial thickness more than 8 mm, but this differ-
ence was not significant. Only the ongoing pregnancy rate
was significantly lower than that in patients with thick en-
dometria (≥14 mm). The clinical pregnancy rate, ongoing
rate and implantation rate (52.38%, 47.62%, and 38.17%,
respectively) were highest in patients with an endometrial
thickness greater than 14 mm (Table 4).
Among 29 patients with thin endometrium (Group 1),
19 patients was secondary infertility before they were in-
cluded in the study. However the number of the patients
with previous IVF attempt in this Group was higher
which may have affected the result; nevertheless the
pregnancy rate in patients in first cycle was quite low
(6.7%, 1/15). The pregnancy rate was 40% among pa-
tients in second cycle (4/10), and three of four patients
among them who had an endometrial thickness more
than 8 mm in previous long GnRH agonist protocol
cycle got pregnant in this GnRH antagonist cycle.
Discussion
Endometrial receptivity is one of the most important
factors in predicting pregnancy after in-vitro fertilization
and embryo transfer. Endometrial thickness has been
utilized as an individual indicator for endometrial recep-
tivity and is measured in the midsagittal plane via transva-
ginal ultrasound, which is considered as a non-traumatic
and a simple method [9]. The endometrial thickness2 Group 3 Group 4
2 N = 1852 N = 63
2145.6 2089.45
1.59 8.67 ± 1.49 8.86 ± 1.45
1.21 3.67 ± 1.22 3.62 ± 1.24
± 5391.63 10166.89 ± 6192.71 9962 ± 4662.25
Table 3 Outcome of pre-embryonic development
Group 1 Group 2 Group 3 Group 4
N = 29 N = 162 N = 1852 N = 63
IVF/ICSI 20/9 129/33 1387/475 53/10
No. of oocyte retrieved 9.34 ± 6.0 10.78 ± 5.41 10.82 ± 5.60 11.02 ± 4.59
No. of oocyte fertilized 7.3 8.0 8.1 8.5
No. of embryo transferred 2.03 ± 0.57 2.01 ± 0.39 2.02 ± 0.37 2.07 ± 0.32
No. of embryo cryopreserved 2.72 ± 3.68 3.01 ± 2.96 2.97 ± 2.94 2.88 ± 2.89
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used.
The effect of endometrial thickness on the success of
IVF-ET had been evaluated by many studies [4-7,10,11].
Recent studies have reported a threshold of <7 mm with a
significant reduction in the implantation rate and preg-
nancy rate [5-7]. Meta-analysis showed that the probabil-
ity of clinical pregnancy in patients with endometrial
thickness less than 7 mm was significantly lower com-
pared to patients with endometrial thickness greater than
7 mm [23.3% versus 48.1%, OR 0.42 (95% CI 0.27–0.67)].
Positive and negative predictive values for the outcome of
clinical pregnancy were 77% and 48%, respectively [5].
Kumbak also found that the clinical pregnancy rate was
26%, miscarriage rate was 31% and live birth rate was 17%
among patients with endometrial thickness less than
7 mm. However, these results were relatively good when
the patient age was <35 years or the number of oocytes
retrieved was over five or the number of available embryos
to transfer was ≥3 [7]. Thus, no conclusive cut-off value of
endometrial thickness has been established.
The findings of endometrium thicker than 14 mm are
controversial. Several authors suggested a detrimental
effect of endometrial thickness of ≥14 mm on pregnancy
rate [12], while the results of other studies have suggested
that a thick endometrium increased the pregnancy rate
[4]. Quintero reported a woman who successfully con-
ceived with an endometrial thickness of 20 mm [13].
Most studies examining the association between endo-
metrial thickness and clinical outcome were performed
using the GnRH agonist protocol. With the antagonistTable 4 Clinical outcome
Group 1 Group 2 Group 3 Group 4
N = 29 N = 162 N = 1852 N = 63
Clinical pregnant rate 17.24%* 38.27 45.63% 52.38%
(5/29) (62/162) (845/1852) (33/63)
Miscarriage rate 20% 11.29% 10.30% 9.09%
(1/5) (7/62) (87/845) (3/33)
Ongoing rate 13.79%* 32.10%* 38.23% 47.62%
4/29 52/162 708/1852 30/63
Implantation rate 10.17%* 23.92% 29.80 38.17%
*P < 0.05.protocol being increasingly used, Al-Inany updated the
Cochran review in 2011. Forty-five randomized trials
(RCT) (n =7511) were included. The results showed that
there was no evidence of a statistically significant differ-
ence in the rates of live births (OR 0.86, 95% CI 0.69 to
1.08), and there was a statistically significant lower inci-
dence of OHSS in the GnRH antagonist group (OR 0.43,
95% CI 0.33 to 0.57) [14].
The GnRH antagonist was also recently introduced in
China. A RCT comparing the antagonist protocol with the
agonist long protocol was performed in normal re-
sponders. Antagonist treatment with a 43.7% clinical preg-
nancy rate was more efficient and safer than treatment
with a long protocol and demonstrated equally high suc-
cess rates [3]. In our study, the clinical pregnancy rate was
44.87% in the normal responder with GnRH antagonist
administration, which was consistent with the results
described above.
There are few studies investigating the association be-
tween endometrial thickness and clinical outcome with
GnRH antagonist administration. However, these results
are controversial [15,16]. Our study is a retrospective
cohort study examining the relationship between endo-
metrial thickness and clinical outcome using the GnRH
antagonist protocol in normal responders. These pa-
tients were aged 20–39 and patients with PCOS and
poor responder were excluded. Our study showed a
positive correlation between endometrial thickness and
clinical outcome, which is consistent with several studies
[6,16]. There were only five clinical pregnancies (17.24%)
in our study, which had an endometrial line of less than
7 mm, of which one was lost. The number of previous
IVF attempts was higher in these patients which might
affect the pregnancy. Although the pregnancy rate was
6.7% in the patients in first cycle, the high previous IVF
attempt is still a limitation of the study. The pregnancy
rate among these patients is similar to the pregnancy
rate (23.3%) in recently meta-analysis although most
women in the meta-analysis were conducted in long
GnRH agonist protocol [5].
Patients with an endometrial thickness between 7–
8 mm had a decreased pregnancy rate, but no significant
difference was shown when compared to patients with
endometrial thickness in 8-14 mm.
Wu et al. Reproductive Biology and Endocrinology 2014, 12:96 Page 5 of 5
http://www.rbej.com/content/12/1/96Implantation is necessary for a successful pregnancy
and requires healthy endometrial receptivity [17]. The
implantation rate (10.17%) was significantly lower in
patients with thin endometrial thickness. Thicker endo-
metria corresponded with higher implantation rates.
These findings were consistent with a clinical pregnancy
rate and ongoing pregnancy rate results.
In patients with thicker endometria (≥14 mm), the
clinical pregnancy rate, ongoing pregnancy rate and
implantation rate increased, but with no difference with
patients with endometrial thickness in 8-14 mm in our
study. This finding was consistent with several recent
studies demonstrating no reduction in pregnancy rate
with a very thick endometrium [6,12].
Our study has some limitations, the most important of
which is its retrospective nature. However, we believe
that the results are of interest because similar studies
had been published with conflicting results.
Conclusions
The results of the present study identified a correlation
between endometrial thickness measured on hCG day
and clinical outcome in normal responders with GnRH
antagonist administration.
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